|Videos|February 20, 2019

What Are Some of the Challenges Involved With Taking PrEP?

W. David Hardy, MD, discusses the challenges health care providers encounter when it comes to patients taking PrEP.

Segment Description: W. David Hardy, MD, adjunct professor of medicine in the Division of Infectious Disease at Johns Hopkins University, explains the challenges that come with taking pre-exposure prophylaxis (PrEP).

Interview transcript (modified slightly for readability):

Contagion®: What are some of the challenges involved with taking PrEP?

W. David Hardy, MD: In terms of challenges for people taking PrEP, the biggest one really falls on the patient after the access question has been answered and the patient has a continuous supply of medication. Trying to get people who are well to do something such as a medical intervention like take a pill every day is not so easy. These individuals who take PrEP of course are well and they're young and they're usually sexually active and they’ve got a lot of stuff going on in their lives, so one of the biggest challenges is really getting someone to remember to take that pill every day. It's not unlike asking women who are sexually active who don't want to become pregnant to take a birth control pill every day, but this is something that I think is going to have some new important changes in the not too distant future to make it easier. Because setting an alarm, putting it by your toothbrush, all these little things we've been telling patients to do for years with their HIV medications have not been transferred to persons taking PrEP.

It works some of the time but most of the studies have shown that adherence with PrEP medications is anywhere between 45 to around 75%. It's not great, and so trying to find ways that would be easier for taking PrEP are really needed.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.